In this episode, PAIN Founder Flindt Andersen and Jason Lachance explore groundbreaking new research on medications like Ozempic, Mounjaro, and other GLP-1 receptor agonists — originally developed for Type 2 diabetes and weight loss — that may also play a significant role in addiction treatment.

Early studies suggest these medications could help reduce cravings and relapse rates. In fact, researchers found that People with alcohol use disorder who were prescribed Ozempic or similar drugs had a 50% lower rate of binge drinking. Individuals with opioid use disorder taking these medications had a 40% lower rate of opioid overdose.

Flindt and Jason break down what these findings could mean for the future of recovery, and how science continues to expand our understanding of addiction and healing.

👉 If you or a loved one needs PAIN: Parents & Addicts In Need help: https://linktr.ee/painnonprofit

🔹 For more on OpiAID: https://opiaid.ai or call Dino Miliotis at (910) 777-4915

🔹 For more on New Perceptions North: https://www.newperceptionsnorth.com